Gleamer

Gleamer is a medical technology company that develops artificial intelligence software for radiology and medical imaging. Founded in Paris, France, in 2017, the company focuses on helping radiologists and other healthcare professionals analyse medical images, identify potentially significant findings, perform measurements, and prepare reports. Its technology is designed for hospitals, diagnostic imaging centres, radiology groups, and other healthcare organizations that handle large volumes of medical examinations.

Gleamer’s main platform is called Gleamer Copilot. It brings together AI applications for different imaging modalities, including X-ray, computed tomography (CT), mammography, and magnetic resonance imaging (MRI). The platform also includes reporting tools intended to support radiologists with documentation and reporting tasks. Instead of requiring healthcare providers to purchase and manage completely separate systems for every application, Gleamer presents its portfolio through a unified environment with a common user experience and deployment gateway.

The company’s development began with BoneView, its AI application for analysing musculoskeletal X-rays. Since then, its portfolio has expanded into chest imaging, bone measurements, paediatric bone maturity assessment, breast imaging, CT analysis, and neurological MRI. Acquisitions have also helped extend its capabilities into additional imaging specialities. In 2025, Gleamer acquired Caerus Medical, adding lumbar spine MRI technology, and Pixyl, which brought neurological MRI applications into its portfolio.

BoneView is one of Gleamer’s established products. It analyses X-ray examinations to identify findings associated with bone trauma, including suspected fractures. The software can highlight areas that may need closer attention and provide preliminary information to support a clinician’s image review. It is designed for use in radiology and emergency care workflows, where timely assessment of musculoskeletal injuries can be important. BoneView supports examinations involving different parts of the skeleton and is intended to assist qualified professionals rather than replace their interpretation.

BoneMetrics is another X-ray application, focusing on musculoskeletal measurements rather than fracture detection. It automates selected measurements from radiographs, including angles and lengths that can be relevant to orthopaedic assessment. Its applications include spinal measurements, such as Cobb angle assessment, which can support the evaluation of spinal deformities. By automating parts of the measurement process, BoneMetrics can help reduce repetitive manual work and provide more consistent measurements. The exact measurements available depend on the product version and its approved intended use.

Gleamer also offers BoneAge, an application for assessing skeletal maturity from hand and wrist radiographs. Bone age assessment is used in paediatric care to help evaluate a child’s skeletal development. The software analyses the relevant radiographic image and provides an automated assessment to support the healthcare professional’s evaluation. This can be useful in clinical environments where bone age examinations are performed regularly and consistent assessment is important.

For chest imaging, Gleamer provides ChestView. This application analyses chest X-rays and highlights selected thoracic findings that may require attention. Its capabilities include identifying findings associated with the lungs, pleural space, airways, and mediastinal or hilar regions. The software presents highlighted regions of interest to help radiologists examine relevant areas of an image. Its US-cleared version has defined indications and limitations, so healthcare providers must follow the applicable product instructions when deploying it.

The company’s CT portfolio includes LungCT and BoneCT. LungCT is designed to analyse CT images for pulmonary nodules, supporting radiologists who review chest examinations. BoneCT focuses on identifying selected secondary bone lesions in CT images. These applications extend Gleamer’s AI-assisted analysis beyond conventional radiography and into cross-sectional imaging. Their use is subject to the regulatory approvals and availability applicable to each market.

BreastView is Gleamer’s mammography solution. It is designed to assist clinicians in identifying suspicious findings on breast imaging examinations. Its portfolio includes functionality for two-dimensional mammography and three-dimensional breast tomosynthesis. These imaging methods are widely used in breast cancer screening and diagnostic assessment. BreastView is intended to provide an additional source of information during image interpretation, with its regulatory status and approved uses varying according to the product version and country.

Gleamer’s MRI portfolio has expanded through its acquisition of Pixyl. The Pixyl.Neuro applications provide tools for analysing neurological MRI examinations. Pixyl.Neuro.MS is designed to support the analysis of multiple sclerosis imaging, while Pixyl.Neuro.BV focuses on brain volumetry. These applications can automatically label selected brain structures or lesions, visualize results, and quantify volumes. Such measurements can be useful in research and clinical workflows where changes in brain structures need to be assessed over time. Their use must follow the applicable instructions and regulatory requirements.

LumbarMR is another MRI-related product in the expanded portfolio. It focuses on lumbar spine imaging and is intended to support the assessment of selected spinal pathologies. However, Gleamer’s regulatory information states that LumbarMR was not yet available for commercial use and was still undergoing its initial CE-marking process at the time of the published information. Its commercial availability should therefore be confirmed directly with the company.

Beyond image analysis, Gleamer has introduced reporting automation capabilities. Voice is presented as an AI reporting agent, while AutoReport is an AI reporting assistant. These tools are intended to support radiologists with voice-based interactions, report preparation, and the completion of documentation. AutoReport can help prefill reporting templates with relevant information, reducing the amount of repetitive typing required during reporting. Voice provides another way for radiologists to interact with reporting workflows. The precise functionality and availability of these tools should be checked with Gleamer, as product capabilities may evolve.

GleamerOS serves as the platform’s central gateway. It is designed to simplify access to the company’s applications, coordinate different solutions, and support deployment within healthcare environments. The gateway can also handle data pseudonymization, helping limit the exposure of identifiable patient information during processing. A unified environment can make it easier for organizations to manage multiple applications and introduce additional tools as their requirements change.

Integration with existing radiology infrastructure is central to the platform’s design. Gleamer describes direct connections with Radiology Information Systems to support worklist prioritization and other workflow functions. Its solutions are also designed for medical imaging environments that use standard imaging workflows and compatible systems. Depending on the deployment, the integration process may involve imaging archives, radiology worklists, reporting templates, and other hospital systems. Healthcare providers should confirm technical compatibility and implementation requirements with Gleamer before purchasing.

Clinical evidence is an important part of the company’s positioning. Gleamer highlights clinical studies and publications relating to its applications, including research on BoneView and other imaging solutions. Its website reports more than 140 international clinical studies and over 60 clinical publications across its portfolio. These figures reflect the company’s stated evidence programme, although the amount and quality of evidence should be considered separately for each application and intended clinical use.

Regulatory authorization is also product-specific. In Europe, selected applications have received Class IIa certification under the Medical Device Regulation, while certain products have received FDA 510(k) clearance in the United States. BoneView also has Health Canada clearance. These approvals do not automatically apply to every application in the Gleamer Copilot portfolio. For example, the regulatory information published by the company distinguishes between products available in Europe, the United States, Canada, and other markets. Healthcare organizations should verify the authorization and intended use of each product in their own jurisdiction before deployment.

Gleamer primarily serves professional healthcare organizations rather than individual consumers. Its customers may include hospitals, emergency departments, radiology networks, orthopaedic services, breast imaging centres, and specialist imaging facilities. Its reporting and workflow tools are particularly relevant to radiology departments looking to coordinate several AI applications within their existing systems. The company’s wider portfolio also makes it relevant to organizations that need imaging analysis across multiple medical specialities.

An important corporate development occurred in March 2026, when RadNet acquired Gleamer SAS for integration into its DeepHealth subsidiary. The acquisition expanded DeepHealth’s radiology AI portfolio and brought Gleamer’s imaging applications into a larger medical imaging technology business. Gleamer continues to present its products under its own brand, while the corporate relationship provides additional context for its ownership and future development.

Overall, Gleamer is a specialist radiology AI platform that combines image analysis, automated measurements, MRI applications, and reporting assistance. Its product range is intended to support professional imaging workflows across several modalities, with a focus on reducing repetitive tasks and helping radiologists review examinations. Its suitability depends on the clinical application, local regulatory status, technical compatibility, and the needs of the healthcare organization.

Pricing

Gleamer does not publish a standard price list for its full product portfolio. Its solutions are marketed to hospitals, radiology groups, imaging centres, and other healthcare organizations through a business-to-business model. Prospective customers are directed to request a demonstration and discuss their requirements with the company. Pricing is likely to depend on the selected applications, examination volume, number of clinical sites, deployment arrangements, and contract terms.

Review

Gleamer offers a broad and increasingly integrated set of radiology AI applications. Its strongest advantage is the range of imaging specialities covered by its portfolio. Healthcare organizations can consider solutions for musculoskeletal X-rays, chest imaging, bone measurements, breast imaging, CT examinations, and neurological MRI within the same product ecosystem.

Another positive aspect is its attention to clinical workflow. Gleamer Copilot is designed around a shared gateway and unified experience, while its reporting tools address documentation tasks that can consume considerable time in radiology departments. Its emphasis on RIS connectivity and worklist prioritization also shows that the platform is intended to fit into existing hospital processes rather than operate only as a standalone image-analysis application.

The company also has a substantial clinical development programme and selected products with regulatory clearances in major markets. Its published clinical studies and certifications provide useful information for healthcare organizations evaluating the technology. However, evidence and authorization must be assessed individually for each product, rather than assuming that the entire portfolio has identical validation or approval.

The main limitations concern implementation, pricing, and availability. Gleamer is an enterprise healthcare solution, so organizations may need technical assessment, system integration, staff training, and commercial discussions before deployment. Its lack of public pricing also makes it difficult to compare costs without requesting a quotation. Additionally, some applications have different regulatory statuses across countries, and certain products may not yet be commercially available in every market.

Gleamer is best suited to established radiology departments and imaging organizations that want to introduce AI assistance across multiple modalities. It may be less suitable for smaller facilities seeking a low-cost, self-service application or consumers looking for personal medical image interpretation. Its value will depend on whether the available applications address the organization’s actual imaging needs and integrate reliably with its clinical systems.